Evidence map›Paper›PMID 37384799›Full record

Trial reportPLoS pathogens2023

The exception that proves the rule: Virulence gene expression at the onset of Plasmodium falciparum blood stage infections.

Jan Stephan Wichers-Misterek, Ralf Krumkamp, Jana Held, Heidrun von Thien, Irene Wittmann, Yannick Daniel Höppner, Julia M Ruge, Kara Moser, Antoine Dara, Jan Strauss and 14 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase I
In one paragraph

Trial report in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02704533 (Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02704533 phase1completednot on this map

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany

TypeinterventionalSponsorSanaria Inc.Ran2016 to 2018Enrolled45ConditionsMalariaArmsPfSPZ Vaccine, PfSPZ Challenge (NF54), PfSPZ Challenge (7G8), Normal saline
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 6 countries.

Jan Stephan Wichers-MisterekBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Ralf KrumkampBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Jana HeldInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Heidrun von ThienBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Irene WittmannInstitute of Microbiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Yannick Daniel HöppnerBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Julia M RugeBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Kara MoserInstitute for Genome Sciences, University of Maryland, School of Medicine, Baltimore, Maryland, United States of America.
Antoine DaraInstitute for Genome Sciences, University of Maryland, School of Medicine, Baltimore, Maryland, United States of America.
Jan StraussBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Meral EsenInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Rolf FendelInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Zita SulyokInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Myriam D JeningaInstitute of Microbiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Peter G KremsnerInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
B Kim Lee SimSanaria Inc., Rockville, Maryland, United States of America.
Stephen L HoffmanSanaria Inc., Rockville, Maryland, United States of America.
Michael F DuffyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
Thomas D OttoSchool of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom.
Tim-Wolf GilbergerBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Joana C SilvaInstitute for Genome Sciences, University of Maryland, School of Medicine, Baltimore, Maryland, United States of America.
Benjamin MordmüllerInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Michaela PetterInstitute of Microbiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Anna BachmannBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.ORCID 0000-0001-8397-7308
Universität Hamburg · DEGerman Center for Infection Research · DEUniversity of Maryland, Baltimore · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DESanaria · USThe University of Melbourne · AUCentre de Recherche Médicales de Lambaréné · GAUniversity of Glasgow · GB

Funding

Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRASER, CLAIRE M., RASKO, DAVID A · 2014 to 2023
$36.5M
Plasmodium Falciparum Whole Sporozoite Malaria VaccineR44AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2005 to 2015
$10.0M
Universal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9M
Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccineR01AI141900 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CARNEIRO DA SILVA, JOANA · 2019 to 2023
$3.9M
NIAID NIH HHS R01 AI141900NIAID NIH HHS R44 AI055229NIAID NIH HHS R44 AI058375NIAID NIH HHS U19 AI110820
6 · The paper itself

Abstract

Controlled human malaria infections (CHMI) are a valuable tool to study parasite gene expression in vivo under defined conditions. In previous studies, virulence gene expression was analyzed in samples from volunteers infected with the Plasmodium falciparum (Pf) NF54 isolate, which is of African origin. Here, we provide an in-depth investigation of parasite virulence gene expression in malaria-naïve European volunteers undergoing CHMI with the genetically distinct Pf 7G8 clone, originating in Brazil. Differential expression of var genes, encoding major virulence factors of Pf, PfEMP1s, was assessed in ex vivo parasite samples as well as in parasites from the in vitro cell bank culture that was used to generate the sporozoites (SPZ) for CHMI (Sanaria PfSPZ Challenge (7G8)). We report broad activation of mainly B-type subtelomeric located var genes at the onset of a 7G8 blood stage infection in naïve volunteers, mirroring the NF54 expression study and suggesting that the expression of virulence-associated genes is generally reset during transmission from the mosquito to the human host. However, in 7G8 parasites, we additionally detected a continuously expressed single C-type variant, Pf7G8_040025600, that was most highly expressed in both pre-mosquito cell bank and volunteer samples, suggesting that 7G8, unlike NF54, maintains expression of some previously expressed var variants during transmission. This suggests that in a new host, the parasite may preferentially express the variants that previously allowed successful infection and transmission. Trial registration: ClinicalTrials.gov - NCT02704533; 2018-004523-36.

Indexed as

CulicidaeMalariaMalaria, FalciparumParasitesAnimalsGene ExpressionHumansPlasmodium falciparumSporozoitesVirulence

Identifiers

PMID37384799
PMCPMC10337978
OpenAlexW4382601516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.